Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Current Drug Discovery Technologies
|
June 10, 2008
Targeting toll-like receptor signaling pathways for design of novel immune therapeutics
Elizabeth Hong-Geller, Anu Chaudhary, Sabine Lauer
Plos One
|
May 3, 2013
A plea for neutral comparison studies in computational sciences
Anne-Laure Boulesteix, Sabine Lauer, Manuel J A Eugster
Biochemistry
|
February 6, 2002
Analysis of cholera toxin-ganglioside interactions by flow cytometry
Sabine Lauer, Byron Goldstein, Rhiannon L Nolan, et al.
Cellular Immunology
|
October 11, 2008
Soluble MD2 increases TLR4 levels on the epithelial cell surface
Sabine Lauer, Yuliya A Kunde, Theresa A Apodaca, et al.
Breast (Edinburgh, Scotland)
|
May 27, 2017
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
Joseph Gligorov, Giuseppe Curigliano, Volkmar Müller, et al.
Cardiovascular Diabetology
|
November 27, 2020
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
João Pedro Ferreira, Subodh Verma, David Fitchett, et al.
The Oncologist
|
July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Kyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
Dimitrios Zardavas, Thomas M Suter, Dirk J Van Veldhuisen, et al.
American Journal of Hypertension
|
May 6, 2020
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
João Pedro Ferreira, David Fitchett, Anne Pernille Ofstad, et al.
Journal of the American Heart Association
|
March 23, 2021
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Current Drug Discovery Technologies
|
June 10, 2008
Targeting toll-like receptor signaling pathways for design of novel immune therapeutics
Elizabeth Hong-Geller, Anu Chaudhary, Sabine Lauer
Plos One
|
May 3, 2013
A plea for neutral comparison studies in computational sciences
Anne-Laure Boulesteix, Sabine Lauer, Manuel J A Eugster
Biochemistry
|
February 6, 2002
Analysis of cholera toxin-ganglioside interactions by flow cytometry
Sabine Lauer, Byron Goldstein, Rhiannon L Nolan, et al.
Cellular Immunology
|
October 11, 2008
Soluble MD2 increases TLR4 levels on the epithelial cell surface
Sabine Lauer, Yuliya A Kunde, Theresa A Apodaca, et al.
Breast (Edinburgh, Scotland)
|
May 27, 2017
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
Joseph Gligorov, Giuseppe Curigliano, Volkmar Müller, et al.
Cardiovascular Diabetology
|
November 27, 2020
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
João Pedro Ferreira, Subodh Verma, David Fitchett, et al.
The Oncologist
|
July 19, 2018
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Kyung Hae Jung, Beyhan Ataseven, Mark Verrill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
Dimitrios Zardavas, Thomas M Suter, Dirk J Van Veldhuisen, et al.
American Journal of Hypertension
|
May 6, 2020
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
João Pedro Ferreira, David Fitchett, Anne Pernille Ofstad, et al.
Journal of the American Heart Association
|
March 23, 2021
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, et al.
Page
of 2